Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Glumetza Scripts Lupin's Strong US Run

Executive Summary

Lupin Ltd. has reported stellar numbers for the fourth quarter ended March 2016, buoyed by US sales of its generic version of Glumetza (metformin HCL extended-release tablets), the Valeant Pharmaceuticals International Inc. drug dumped earlier this year by pharmacy benefits manager, Express Scripts Holding Co.


Related Content

US Price Pressure Clouds Lupin Outlook – Can Its Pipeline Deliver?
Lupin's Metformin US Outlook Stays Sunny; Russian Buy Under Review
India Q1 Results Preview: Exclusivity, Compliance Are Key Talking Points
Valeant Bends On Hospital Discounts; 'Left' Turn Ahead
Lupin Q2 Profits Slump But US Approvals Pick-Up In Sight
Lupin takes "more shots at the goal" with $880m US buy





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts